Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai Henlius Biotech, Inc.
上海復宏漢霖生物技術股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2696)

VOLUNTARY ANNOUNCEMENT

INCLUSION OF HANSIZHUANG (SERPLULIMAB INJECTION) AND OTHERS IN THE NATIONAL REIMBURSEMENT DRUG LIST

A. INTRODUCTION

This announcement is made by Shanghai Henlius Biotech, Inc. (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Company.

The board of directors (the "**Board**") of the Company is pleased to announce that, recently, HANSIZHUANG (serplulimab injection) ("**HANSIZHUANG**") has been newly included in Category B of the National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance (Year 2026) (the "**NRDL**"), for the indication of its all indications approved for marketing in Chinese Mainland (excluding Hong Kong, Macau and Taiwan regions of China, same as below). In addition, the second indication of FUTUONING (Fovinaciclib Citrate Capsules) ("**FUTUONING**") has also been newly included in NRDL. The new edition of the NRDL will officially come into effect on 1 January 2027.

B. ABOUT HANSIZHUANG AND FUTUONING

HANSIZHUANG is an innovative anti-PD-1 monoclonal antibody independently developed by the Company, which was approved for marketing in Chinese Mainland for indications including the combination with chemotherapy for the first-line treatments of squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC) and non-squamous non-small cell lung cancer (nsNSCLC) as well as the combination with chemotherapy for neo-/adjuvant treatment for gastric cancer. Meanwhile, HANSIZHUANG was also approved for marketing in the European Union, United Kingdom, Indonesia, Cambodia, Thailand, Malaysia, Singapore, India and other countries/regions respectively, and has been granted Orphan-drug Designation by drug administrations in the United States, Switzerland, South Korea and other countries/regions, respectively.

In addition, the Company is in the process of advancing a number of clinical studies of HANSIZHUANG and related combination therapies globally, covering a wide range of indications such as lung cancer, head and neck squamous cell carcinoma and colorectal cancer. As of the date of this announcement, the latest progress of HANSIZHUANG and the relevant combination therapies is as follows:

Product/Combination therapy	**Indications**	**Latest progress**
HANSIZHUANG + chemotherapy	Extensive-stage small cell lung cancer	Bridging study in the United States Bridging study in Japan
	Limited-stage small cell lung cancer (HANSIZHUANG in combination with chemotherapy and concurrent radiotherapy)	Phase 3 clinical trial in Chinese Mainland, the United States, Australia and EU countries (international multi-center trial)
HANSIZHUANG + bevacizumab + chemotherapy	Metastatic colorectal cancer	Phase 2/3 clinical trial in Chinese Mainland, Japan and Indonesia (International multi-center trial)
HLX07 (recombinant anti-EGFR humanised monoclonal antibody injection) + HANSIZHUANG + chemotherapy	Squamous non-small cell lung cancer	Phase 2/3 clinical trial in Chinese Mainland
HLX43 (an antibodydrug conjugate targeting PD-L1) + HANSIZHUANG	Solid tumours	Phase 1b/2 clinical trial in Chinese Mainland

FUTUONING is an in-licensed innovative CDK4/6 small molecule inhibitor of the Company. In May 2025, FUTUONING was approved for marketing in Chinese Mainland. The first indication being approved is in combination with Fulvestrant for the treatment of adult patients with hormone receptor (HR) positive and human epidermal growth factor receptor-2 (HER2) negative recurrent or metastatic breast cancer, who have experienced disease progression after prior endocrine therapy. In September 2025, the second indication of FUTUONING, i.e. in combination with an aromatase inhibitor as initial endocrine therapy for the treatment of adult patients with hormone receptor (HR) positive and human epidermal growth factor receptor-2 (HER2) negative locally advanced or metastatic breast cancer, was approved in Chinese Mainland.

C. IMPACTS ON THE COMPANY

The inclusion of HANSIZHUANG and a new indication of FUTUONING in the NRDL reflects the recognition by the National Healthcare Security Administration on these products' clinical values, benefits to patients and innovation level, etc. It will enhance products' accessibility and reduce the medication burden on patients, as well as is beneficial for the marketing and sales layout of these products.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Xingli Wang
Chairman

Hong Kong, 15 November 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Xingli Wang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yuqing Chen, Ms. Xiaohui Guan and Dr. Yi Liu as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan and Dr. Ruilin Song as the independent non-executive directors.